DahlöfCGHMathewNCardiovascular safety of 5HT1B/1D agonists—Is there a cause for concern?Cephalalgia1998;
18:
532–8
2.
DahlöfCGHFalkLRisenforsMLewisCPSafety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/ or pain in the chest, neck, and/or throat following sumatriptan.Cephalalgia1998;
18:
546–51
3.
Freedom of Information.
Sumatriptan Adverse Event Reporting, United States Food and Drug Administration
4.
RosenthalSChenRThe reporting sensitivities of two passive surveillance systems for vaccine adverse events.Am J Publ Health1995;
85:
1706–9
5.
SwanLBimieDHHoodSThe effects of subcutaneous naratriptan 1.5 mg on the systemic, pulmonary, and coronary circulation in patients with suspected coronary artery disease.Cephalalgia1997;
17:
428
6.
Summary Basis of Approval, Naratriptan NDA
20-763, United States Food and Drug Administration,
1998
7.
MacIntyrePDBhargavaBHoggKJGemmillJDHillisWSEffect of i.v. sumatriptan, a selective 5HT1 agonist on central haemodynamics and the coronary circulation.Br J Clin Pharmacol1992;
54:
541–6
8.
MacIntyrePDBhargavaBHoggKJGemmillJDHillisWSEffect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation.Circulation1993;
87:
401–5
9.
Summary Basis of Approval, Zolmitriptan NDA
20-768, United States Food and Drug Administration,
1997
